Pimecrolimus Cream 1% plus topical corticosteroid in patients with severe atopic dermatitis

Journal of Drugs in Dermatology, Nov-Dec, 2005

This study is currently recruiting patients. Sponsored by Novartis. Atopic dermatitis, also called eczema, is characterized by redness, papulation (skin elevation), and pruritus (skin itching). The active ingredient of pimecrolimus inhibits the T-cell activation. These cells are involved in the inflammatory component of the disease. This study will test the safety of pimecrolimus Cream 1% with topical corticosteroid treatment (commonly used in eczema) in patients with severe atopic dermatitis.

Condition           Intervention           Phase

Dermatitis, Atopic  Pimecrolimus cream 1%  Phase IV

Study ID Numbers: ASM981C2439

ClinicalTrials.gov Identifier: NCT00121381